Comparison

Semaglutide vs tirzepatide

At a glance

Mechanism difference: single vs dual receptor agonism

The core pharmacological difference is how each molecule signals to the body. Semaglutide binds and activates only the GLP-1 (glucagon-like peptide-1) receptor, mimicking a natural gut hormone that slows gastric emptying, increases satiety, and stimulates insulin release. Tirzepatide binds and activates both the GIP (gastric inhibitory polypeptide) receptor and the GLP-1 receptor — making it the only widely prescribed dual receptor agonist as of 2026.

The clinical rationale for dual mechanism is that GIP and GLP-1 signal complementary metabolic pathways. GIP influences fat metabolism and insulin sensitivity through different downstream pathways than GLP-1. Combined activation appears to produce greater appetite suppression and weight reduction than GLP-1 activation alone in clinical trials of FDA-approved branded products, though individual response varies.

Clinical evidence: trial data references brand-name products only

The headline efficacy numbers most often cited in patient-facing GLP-1 marketing come from clinical trials of FDA-approved branded products. The STEP 1 trial (NEJM 2021) studied 2.4 mg weekly brand-name Wegovy and demonstrated approximately 14.9% mean weight loss over 68 weeks in adults with overweight or obesity treated alongside lifestyle intervention. The SURMOUNT-1 trial (NEJM 2022) studied 15 mg weekly brand-name Zepbound and demonstrated approximately 22.5% mean weight loss over 72 weeks in a comparable adult population.

No large-scale published clinical trials have specifically examined compounded versions of either medication. The pharmacological assumption is that the same active ingredient at the same dose produces the same effect — but this is an assumption, not a clinical conclusion. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products. Individual results vary substantially based on dose, adherence, lifestyle factors, and individual response.

Cost: compounded vs brand-name

Compounded semaglutide is generally less expensive than compounded tirzepatide because the active pharmaceutical ingredient (API) for tirzepatide is more expensive at the wholesale level. Through Cora Health, the difference is reflected in the all-inclusive monthly rate: the Essential Plan (compounded semaglutide) starts at $99/month on the annual commitment, while the Premium Plan (compounded tirzepatide) starts at $135/month on the annual commitment. Both prices are all-inclusive — covering the licensed-provider consultation, the medication, free expedited shipping, and ongoing provider monitoring with no separate membership or per-dose surcharge.

For brand-name FDA-approved products, retail list pricing is approximately $1,349/month for Wegovy (brand semaglutide) and $1,086/month for Zepbound (brand tirzepatide). Manufacturer direct-pay programs — NovoCare Pharmacy for Wegovy and LillyDirect for Zepbound — have created lower self-pay tiers of approximately $199-$499/month for eligible patients.

How to choose between semaglutide and tirzepatide

The clinical decision is individual and should be made in consultation with a licensed healthcare provider based on medical history, treatment goals, prior medication tolerance, and cost considerations. Some general patterns:

• Compounded semaglutide is often selected by patients prioritizing the lowest monthly cost on a GLP-1 program, patients who tolerate single-receptor GLP-1s well, or patients early in their weight management journey.
• Compounded tirzepatide is often selected by patients who want the dual-mechanism profile, patients who have plateaued on semaglutide and want greater appetite suppression, or patients whose providers have evaluated dual-receptor agonism as more clinically appropriate for the individual case.
• The decision should always involve a licensed provider. Cora Health connects patients with licensed providers at Wasef Health, PC, who evaluate each patient individually and recommend the most appropriate plan. Cora Health does not prescribe medication — providers do.

Frequently asked questions

What is the difference between semaglutide and tirzepatide?

Semaglutide is a single-receptor agonist that activates only the GLP-1 (glucagon-like peptide-1) receptor. Tirzepatide is a dual-receptor agonist that activates both the GIP (gastric inhibitory polypeptide) and GLP-1 receptors. The dual mechanism in tirzepatide is associated with greater mean weight loss in clinical trials of FDA-approved branded products, though individual results vary. Both molecules slow gastric emptying, increase satiety, and support weight management when paired with lifestyle changes.

Is tirzepatide more effective than semaglutide for weight loss?

In head-to-head clinical evaluation of FDA-approved branded products, tirzepatide has produced greater mean weight loss than semaglutide in pivotal Phase 3 trials. The STEP 1 trial (NEJM 2021) studied 2.4 mg weekly brand-name Wegovy (semaglutide) and demonstrated approximately 14.9% mean weight loss over 68 weeks alongside lifestyle intervention. The SURMOUNT-1 trial (NEJM 2022) studied 15 mg weekly brand-name Zepbound (tirzepatide) and demonstrated approximately 22.5% mean weight loss over 72 weeks alongside lifestyle intervention. Both trials studied FDA-approved branded products. Compounded versions of either molecule are not therapeutically equivalent to the branded products and have not been studied in equivalent trials. Individual results vary substantially based on dose, adherence, lifestyle factors, and individual response.

Which has more side effects, semaglutide or tirzepatide?

Both medications share the same general side effect profile typical of GLP-1 receptor agonists: nausea, diarrhea, vomiting, constipation, abdominal pain, and reduced appetite, particularly during titration. Side effect intensity tends to peak in the early weeks of treatment or after dose increases and typically improves over time. Tirzepatide may have a marginally different gastrointestinal side effect profile due to its dual mechanism, but the differences are clinically modest. A licensed provider can help determine which medication is best suited to an individual based on health history, prior medication tolerance, and treatment goals.

Which costs less, semaglutide or tirzepatide?

Compounded semaglutide is generally less expensive than compounded tirzepatide. Through Cora Health, the Essential Plan (compounded semaglutide) starts at $99/month all-inclusive on the annual plan, while the Premium Plan (compounded tirzepatide) starts at $135/month all-inclusive on the annual plan. Brand-name pricing follows the same pattern: brand Wegovy retails around $1,349/month list price; brand Zepbound around $1,086/month list price (with manufacturer direct-pay programs like NovoCare and LillyDirect offering lower self-pay tiers).

Should I choose semaglutide or tirzepatide?

The choice between compounded semaglutide and compounded tirzepatide is a clinical decision that should be made in consultation with a licensed healthcare provider based on individual health profile, treatment goals, prior medication tolerance, and cost considerations. Cora Health connects patients with licensed providers at Wasef Health, PC who evaluate each patient individually and recommend the most appropriate plan. Cora Health does not prescribe medication — providers do, based on clinical evaluation.

Can I switch from semaglutide to tirzepatide or vice versa?

Yes, transitions between GLP-1 medications are common in clinical practice and are typically guided by the prescribing provider. Patients who do not tolerate one medication well or who plateau on weight loss may transition to the other under provider supervision, with appropriate dose titration. Switching between compounded products and brand-name products is also typically straightforward when clinically appropriate. Patients should never adjust their own dose or switch medications without provider guidance.

Are compounded versions of semaglutide and tirzepatide the same as the brand-name products?

No. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not therapeutically equivalent to brand-name FDA-approved products (Ozempic and Wegovy for semaglutide; Mounjaro and Zepbound for tirzepatide). The active ingredient name is the same, but compounded versions are prepared by state-licensed pharmacies rather than FDA-inspected commercial manufacturers. The FDA does not review compounded medications for safety, effectiveness, or manufacturing quality before they reach patients. Compounded versions may also differ in salt form (e.g., semaglutide sodium vs semaglutide acetate), excipients, and quality controls across different pharmacies.

Talk to a licensed provider about your options

Cora Health connects you with licensed providers at Wasef Health, PC for personalized evaluation. Compounded semaglutide from $99/month; compounded tirzepatide from $135/month — all-inclusive.